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Abstract
Although acute tropical pulmonary eosinophilia (TPE) is well
recognized as a manifestation of filarial infection, the processes
that mediate the abnormalities of the lung in TPE are unknown.
To evaluate the hypothesis that the derangements of the lower
respiratory tract in this disorder are mediated by inflammatory
cells in the local milieu we utilized bronchoalveolar lavage to
evaluate affected individuals before and after therapy. Inflam-
inatory cells recovered from the lower respiratory tract of indi-
viduals with acute, untreated TPE (a = 8) revealed a striking
eosinophilic alveolitis, with marked elevations in both the pro-
portion of eosinophils (TPE 54±5%; normal 2±5%; P < 0.001)
and the concentration of eosinophils in the recovered epithelial
lining fluid (ELF) (TPE 63±20 X 103/Al; normal 03±0.1
X 103/jl; P < 0.01). Importantly, when individuals (a = 5) with
acute TPE were treated with diethylcarbamazine (DEC), there
was a marked decrease of the lung eosinophils and concomitant
increase in lung function. These observations are consistent with
the concept that at least some of the abnormalities found in the
lung in acute TPE are mediated by an eosinophil-dominated in-
flammatory process in the lower respiratory tract.
Introduction
Tropical pulmonary eosinophilia (TPE)' is an interstitial lung
disease that results from a heightened immunologic response to
the human filarial parasites, Wuchereria bancrofti and Brugia
malayi (1). TPE has been reported from filarial endemic regions
all over the world, but it is especially prevalent in India and
Southeast Asia (1, 2). For reasons that are not yet clear, indi-
viduals with TPE respond to filarial infections with vigorous
immune responses and severe clinical manifestations that con-
trast markedly with those ofmost individuals living in the filarial
endemic region, who often have filarial infections but commonly
show highly suppressed immunologic responses and minimal
clinical reactions (2-4).
Individuals with acute TPE characteristically present with
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cough, dyspnea, nocturnal wheezing, and occasionally fever, an-
orexia, and weight loss. Their chest x-rays have diffuse reticu-
lonodular infiltrates, and pulmonary function tests show pri-
marily restrictive defects with mild obstruction (1, 5, 6). Unlike
results obtained from normals and individuals with other man-
ifestations offilarial infection, laboratory studies from individuals
with acute TPE demonstrate marked peripheral blood eosino-
philia and high serum concentrations of IgE and filarial-specific
IgG and IgE antibodies (1-5). Although most individuals with
acute TPE have a rapid clinical response to a standard course
ofdiethylcarbamazine (DEC), with reduced cough and dyspnea,
in some individuals the pulmonary disease progresses to a chronic
form that results in interstitial fibrosis and permanent loss of
lung function (6-9).
The current hypothesis concerning the pathogenesis ofTPE
suggests that it begins with a lung parenchymal inflammation
in persons highly sensitized immunologically to filarial parasites.
This inflammation is initiated by microfilariae that have been
released from lymphatic dwelling adult worms into the circu-
lation and cleared in the pulmonary vasculature. According to
this concept, these trapped microfilariae degenerate and release
their antigenic constituents that trigger local inflammatory and
immune processes (9-11). Consistent with this concept, very
limited morphologic data has revealed evidence ofdegenerating
microfilariae and diffuse inflammation in the lung parenchyma
(6, 9, 10, 12, 13).
In this context, it is reasonable to hypothesize that the clinical
and physiologic pulmonary abnormalities characteristic ofTPE
are mediated, at least in part, by the accumulation of inflam-
matory cells in the lung parenchyma. As a first step in defining
the inflammatory processes, we have utilized the technique of
bronchoalveolar lavage to sample and analyze the inflammatory
cells from the lower respiratory tract of individuals with acute
TPE and to correlate the status of this inflammation with the
changes in lung function observed following therapy with DEC.
Methods
Study population
All individuals in the study population were residents of the area sur-
rounding Madras, India, a region endemic for bancroftian filariasis.
Clinical evaluation ofeach individual included detailed history, physical
examination, chest x-rays, pulmonary function tests (using P. K. Morgan
pulmonary function test apparatus), and blood and stool examinations
for the presence ofother parasites. To determine the immunologic status
of the study population to filaria, each individual had total serum IgE
measured by a standard radioimmunosorbant technique (14) (Pharmacia
Fine Chemicals, Piscataway, NJ) and specific IgG filarial antibody de-
termined by an enzyme immunoassay (15) using antigen prepared from
Brugia malayi adult worms (14).
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Individuals with acute TPE. The diagnosis of acute TPE was estab-
lished in eight individuals based on the accepted criteria (1) of residence
in the endemic area of southern India, recent onset of symptoms, chest
x-ray infiltrates, lung function abnormalities, peripheral eosinophilia,
high total serum IgE, and high serum titers of antifilarial IgG (Table I).
In addition, two individuals complained of fever and weight loss.
Normals. Seven normal nonsmokers from the Madras area were
evaluated as controls (Table I). None had respiratory symptoms or ab-
normal physical findings, and all had normal chest x-rays and normal
pulmonary function tests. None had elevated peripheral blood eosinophil
counts, high serum concentrations of total IgE, or high concentrations
of filarial-specific IgG.
Individuals with elephantiasis. Four individuals who had elephan-
tiasis, a manifestation offilarial infection with no pulmonary involvement,
were also evaluated (Table I). Except for the chronic problem of ele-
phantiasis, all individuals were asymptomatic at the time of evaluation,
with normal chest examinations, chest x-rays and pulmonary function
tests. Mean blood eosinophil counts were normal, but there were mildly
elevated serum IgE levels. Antifilarial IgG antibody titers were distinctly
lower than those of the TPE patients.
Individuals with asthma. Since acute TPE and asthma are both char-
acterized by cough, dyspnea, wheezing, and blood eosinophilia, four in-
dividuals with asthma but no evidence of filarial infection were also
evaluated (Table I). The diagnosis of asthma was based on a history of
wheezing, exertional dyspnea, and clinical response to therapy with oral
bronchodilators. All had mild blood eosinophilia, but total IgE and filaria-
specific IgG levels were markedly lower than those associated with TPE.
Three had cough, dyspnea, and wheezing, and two had wheezing on
physical examination. When evaluated, all had normal pulmonary func-
tion tests. One individual had a chest x-ray showing a scattered mild
nodular pattern; however, this individual had normal pulmonary function
tests and normal bronchoalveolar lavage findings.
Collection oflung effector cellsfrom the lower
respiratory tract
All studies were carried out under protocols approved by the National
Institutes of Health, USA, and the Indian Council of Medical Research,
India. In all cases, the procedures to be performed were explained in
English or the local language by a member of the staff and consent was
obtained.
Bronchoscopy and bronchoalveolar lavage were performed under
local anesthesia without complications in the outpatient facility of the
Tuberculosis Research Center, Madras, India. Since individuals in two
of the study groups, acute TPE and asthma, were predisposed to bron-
chospagm, all individuals, except fog the normal subjects, received in-
travenous aminophylline (0.5 mg/ml at 100 ml/h) before, during, and
after the procedure. One individual in the acute TPE group and one
individual in the asthma group developed moderate bronchospasm fol-
lowing the procedure; in both cases, this was easily treated with additional
intravenous aminophylline, inhaled isoproterenol, and nasal oxygen. All
individuals were observed for 3 h after bronchoscopy and then discharged
from the clinic. When reevaluated 24 h later, one individual complained
of a transient fever the evening following bronchoscopy, but, otherwise,
there were no significant complications from the procedure.
Lung effector cells from the lower respiratory tract were obtained by
bronchoalveolar lavage with 300 ml of saline, as previously described
(19). Briefly, 100 ml of sterile saline in five 20-ml aliquots was infused
through a fiberoptic bronchoscope into each of three lobes ih the lower
respiratory tract. The cells and lavage fluid were recovered by gentle
suction after each aliquot was infused. The cells recovered by lavage were
counted on a hemocytometer, and lavage cell differentials were deter-
mined using filter preparations stained with hematoxylin and eosin (20).
Evaluation ofthe concentration ofeosinophils
in lung and blood
To estimate the relative concentration between eosinophils in the lower
respiratory tract and in the blood, the total numbers of eosinophils re-
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moved by bronchoalveolar lavage were referenced to the amount of the
total lower respiratory tract epithelial lining fluid (ELF) recovered in the
same procedure. The amount of ELF recovered was estimated using
urea as an internal standard, as previously described (21). The percent
recovery ofthe lavage fluid from the various groups were: normals 60+4%,
acute TPE 49±1%, asthma 40±7%, and elephantiasis 60±4%.
Evaluation ofthe morphology ofeosinophils
To evaluate the morphology ofthe eosinophils, blood and lung cells were
pelleted by centrifugation, fixed with 3% glutaraldehyde in 0.1 M phos-
phate buffer, pH 7.2, washed with several changes of buffer, postfixed
with 1% osmium tetroxide in phosphate buffer, dehydrated with ethanol
and propylene oxide and embedded in Polybed 812. Ultrathin sections
were stained with uranyl acetate and lead citrate and examined with a
transmission electron microscope at an accelerating voltage of 80 kV.
Evaluation of the eosinophil granule crystallized core and matrix was
performed on 100 randomly chosen eosinophils per study subject.
Short-term effects oftreatment on acute TPE
To determine the short-term effects oftherapy on the alveolitis of acute
TPE, five of the individuals with acute TPE were reevaluated by bron-
choalveolar lavage 6-12 d after starting therapy with DEC (6 mg/kg per
d). To determine if changes in lung function accompanied changes in
the alveolitis associated with therapy, pulmonary function tests were
carried out before the repeat lavage procedures. To evaluate the long-
term results ofa standard 3-wk course oftherapy, three ofthese individuals
were reevaluated one year later by bronchoalveolar lavage and lung
function tests.
Data analysis
All data except quantitation ofimmunoglobulins (Table I) are presented
as mean±SEM. Since log-transformed serum IgE values are normally
distributed, the results for total serum IgE (Table I) are presented as the
geometric mean with 95% confidence limits. Likewise, the antifilarial
IgG values (Table I) are presented as the geometric mean with 95% con-
fidence limits, as previously reported (1 1).
All results between groups were compared using the two-tailed Stu-
dent's t test; paired results from individuals were compared using the
paired t test. Paired results before and after therapy were compared in
terms of percent change using the one sample t test.
Results
Characterization oflung inflammatory cell population
in acute TPE
Acute TPE was associated with an intense alveolitis (Table II).
The total number of inflammatory cells recovered from the la-
vage fluid of individuals with acute TPE (241±38 X i0~) was
approximately fourfold greater than that ofany ofthe three con-
trol populations (total number of cells recovered from normals,
34+7 X 106; patients with elephantiasis, 66+15 X 106; and asth-
matics, 30±18 X 106). This was true whether all individuals or
only nonsmokers were considered (P < 0.05, TPE compared to
all other groups).
When referenced in terms of the total volume of epithelial
lining fluid recovered by the lavage procedure, it was apparent
that the increase in number of recovered inflammatory cells in
acute TPE was a reflection of the markedly increased concen-
tration ofinflammatory cells in fluid lining the epithelial surface
of the lower respiratory tract. In this regard, acute TPE patients
had a lavage cell concentration at least four times greater than
any of the control populations (P < 0.025, Table II).
Bronchoalveolar lavage cell differentials revealed that the
eosinophil was the predominant type of inflammatory cell re-
covered from the lavage fluid of patients with acute TPE (Table
H, Fig. 1). There were no significant differences in the percentages
of recovered lymphocytes or neutrophils among normal indi-
viduals or those with acute TPE, elephantiasis, or asthma. In
marked contrast, the percentage of eosinophils recovered from
individuals with acute TPE was dramatically increased compared
to that of all other groups (P < 0.001, TPE compared to all
others). As a consequence, the percentage of macrophages re-
covered in the acute TPE group was proportionately reduced
compared to that ofthe other clinical groups (P < 0.005). There
were no unusual cell types such as basophils, mast cells, or plasma
cells recovered from the lower respiratory tract ofany individual
studied, and epithelial cells always represented < 5% ofthe cells
recovered. Furthermore, there were no microfilariae identified
in the lavage fluid or on the filter preparations.
Evaluation of the concentration of each cell type in the re-
covered ELF demonstrated that the concentration ofeosinophils
in individuals with acute TPE (63±20 X 103 eosinophils/gl ELF)
was at least 21-fold greater than that of any other group. In
contrast, the concentration of lymphocytes, neutrophils, and
macrophages was similar, although the TPE patients had a mild
increase in neutrophils, among all study groups (P> 0.2). Thus,
the pulmonary inflammation of acute TPE was characterized
by an intense eosinophilic alveolitis demonstrated by marked
increases in both the percentage of eosinophils recovered by la-
vage and in the concentration of eosinophils in the epithelial
lining fluid of the lower respiratory tract.
Relative concentration ofeosinophils in peripheral blood
and lung ELF
When direct comparisons oflung and blood eosinophil concen-
trations were made, it was apparent that the individuals with
acute TPE had a 3- to 20-fold greater concentration ofeosinophils
Table II. Analysis ofCells and Fluid Recovered by Bronchoalveolar Lavage
Cell density*
Cell differential*
[Total cells X 103i/ [M x IoP]/ [L X 10i1/ [N X 103j/ [E X IOCP/
Study group n M L N E [j1ELF] [11ELF] [$d ELF] [i ELF] Lul ELF]
Acute TPE 8 32±5 10±2 4±3 54±5 88±17 27±6 8±2 5±3 47±11
Normals 7 76±4 21±4 2±0 2±0 20±6 22±6 4±1 <1 <1
Elephantiasis 4 72±6 25±5 1±0 3±1 25±6 16±7 5±0 <1 <1
Asthma 4 66±4 22±6 2±1 10±4 19±9 13±6 4±1 <1 3±2
* Cell differentials on filter preparations; macrophages (M), lymphocytes (L), neutrophils (N) and eosinophils (E). * Cell density determined as
[number of cells of each type recovered]/[amount of ELF recovered]; ELF is epithelial lining fluid (21).
218 Pinkston et al.
Downloaded on August 19, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/113050
80H
a
0
LU
I-.
z
'U
'U
a.
60
9 8
8
so
0o A
- GA
S
0
40k s
20H
.
0
S
0
0a o
A
0o
S
S
AonA S
MACROPHAGES
0
L4~mA ~ A
TPE b= TE t="]
No_Alm Nonvd Am
LYMPHOCYTES NEUTROPHILS
Nor" A
EOSINOPHILS
Figure 1. Bronchoalveolar lavage cell differentials from individuals
with acute TPE (.), normals (o), individuals with elephantiasis (0),
and individuals with asthma (A). The percentage of each cell type re-
covered is represented for each individual in the various groups.
in their lung ELF than in their blood (P < 0.01) (Fig. 2). For
other clinical groups, by contrast, there was no significant dif-
ference between the concentration of eosinophils in lung and
blood (P > 0.2, all comparisons). Since the concentration of
eosinophils in ELF was much greater than would be expected
from passive infiltration ofperipheral blood eosinophils into the
lungs, these observations suggest that the lung eosinophilia of
individuals with acute TPE represents a selective process of eo-
sinophil accumulation in the lower respiratory tract.
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Figure 2. Comparison of the concentration of eosinophils in ELF of
the lower respiratory tract to that of blood of individuals in the study
groups. Shown are data from normals, individuals with acute TPE, in-
dividuals with elephantiasis, and individuals with asthma. The concen-
tration of lung eosinophils in ELF is expressed as the number of eosin-
ophils per microliter of epithelial lining fluid recovered by bronchoal-
veolar lavage. The concentration of blood eosinophils was determined
by quantitation of the number of eosinophils contained per microliter
of blood for the same individuals. The data for lung and blood of each
individual are indicated as -0-.
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Morphological changes ofeosinophils
Electron microscopic examination disclosed marked alterations
in the morphology of eosinophils in the lavage fluid recovered
from individuals with acute tropical eosinophilia. In comparison
with eosinophils from simultaneously processed blood and lavage
fluid from normal individuals (Fig. 3 A, B), the lung eosinophils
from individuals with acute tropical eosinophilia (Fig. 3 C-G)
showed marked alterations which consisted of severe degranu-
lation with loss of both the cores and the peripheral portions of
the granules. In many granules, only part ofthe crystalline core
remained, surrounded by an electron-lucent peripheral zone (Fig.
3 D); the cores often also had electron-lucent central portions.
Granule fusion was also present (Fig. 3 E), and the granules
exhibited a considerable heterogeneity of morphological changes
(Fig. 3 F) from empty granules to various shaped electron hy-
podense cores to empty or an electron hypodense periphery sur-
rounding the cores (Fig. 3 G). The nuclei of these cells retained
their usual morphology. The finding of marked loss of granule
material correlates with the vacuolated appearance exhibited by
such eosinophils in light microscopic preparations stained by
the Giemsa method. The lung eosinophil granules ofindividuals
with acute TPE had a greater loss of the crystallized core and
matrix than the lung eosinophils of normals (percent lung eo-
sinophils showing total loss of granule matrix in acute TPE
88±3%, normals 48±13%, P < 0.01).
Effects oftreatment on the alveolitis ofacute TPE
Since acute TPE responds clinically to DEC, one would antic-
ipate that the intense eosinophilic alveolitis would resolve fol-
lowing treatment. To examine this question directly, five indi-
viduals from the acute TPE group were treated with DEC and
reevaluated 6-12 d later. Interestingly, even in this short period
of therapy there was a profound fall in the percentage of lung
eosinophils (mean decrease of26±5%; P < 0.01; Fig. 4 A). Con-
sistent with this observation, the concentration of eosinophils
in the recovered ELF also decreased in all five patients after
DEC therapy (Fig. 4 B). Thus, the eosinophilic alveolitis ofacute
TPE responded rapidly to therapy with DEC. Peripheral blood
eosinophilia also fell significantly after therapy in these same
five individuals (8.7±1.2 X 103 eosinophils/gl before to 2.2±0.5
eosinophils/,l after treatment; P < 0.05), but there were no im-
mediate changes in the total serum IgE (before 30,683 ng/ml,
after 36,733 ng/ml) and serum antifilarial IgG titers (before
59,200 U/ml, after 70,933 U/ml) after the first 1-2 wk of therapy
with DEC (geometric means, P> 0.2, both comparisons).
Clinical evaluation of these same five individuals with acute
TPE 6-12 d after starting DEC revealed improvement in their
lung abnormalities that paralleled the resolution of the eosino-
philic alveolitis. All individuals had less cough, dyspnea, noc-
turnal wheezing, and fever, four ofthe five showed improvement
in the chest x-ray abnormalities; and pulmonary function tests
demonstrated increased vital capacity and FEVI (Fig. 4 C). Three
of the five individuals treated with DEC were available for re-
evaluation 1 yr later. The proportion and concentration of eo-
sinophils in the lung continued to decline and the lung function
tests markedly improved in each individual (Fig. 4). In addition,
there was a marked decline in serum titers of IgG antifilarial
antibodies.
Discussion
Evaluation of individuals with acute tropical pulmonary eosin-
ophilia demonstrated that this disease is characterized by an
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Figure 3. Electron micrographs of eosinophils from normal individu-
als and patients with acute tropical eosinophilia. (A) Typical appear-
ance of eosinophil in blood of a normal individual, with cytoplasmic
granules that contain dense cores (X 11,500). (B) Eosinophil in bron-
choalveolar lavage fluid of a normal individual. The peripheral por-
tions of some of the granules appear lucent in comparison with those
of normal blood eosinophils, but the dense central cores are still evi-
dent (X 13,500). (C) Eosinophil from bronchoalveolar lavage fluid of
a patient with acute tropical eosinophilia. There is marked loss of
granule content and disappearance ofthe dense central cores
(X 11,500). (D) and (E) Cytoplasm of eosinophils in ravage fluid of in-
dividuals with acute tropical pulmonary eosinophila. The granules
show loss of central dense cores, loss of peripheral matrix, cytoplasmic
vacuoles, and granule fusion (x 22,000). (F) and (G) High power view
of cytoplasm of eosinophils in lavage fluid of individuals with acute
tropical pulmonary eosinophilia. There are contrasting hypodense and
dense central cores (x 35,000).
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intense eosinophilic inflammatory process in the lower respi-
ratory tract. Interestingly, while TPE is typically associated with
some of the highest levels of blood eosinophilia of any human
disorder (1), the concentration of eosinophils in the epithelial
lining fluid of the lower respiratory tract was many fold greater
than that in blood, an observation suggesting that eosinophils
Figure 3 (Continued)
accumulate selectively in the lung parenchyma. Furthermore,
when these individuals were treated with DEC, the lung eosin-
ophilia rapidly began to resolve within the first 2 wk oftherapy,
and this resolution was paralleled by an improvement in lung
function. Importantly, reevaluation 1 yr later demonstrated that
the proportion and concentration of eosinophils in both lung
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Figure 4. Effects of diethylcarbamazine on the individuals with acute
TPE. Five individuals with acute TPE were evaluated by bronchoal-
veolar lavage and pulmonary function tests before and after therapy.
Each individual was treated with DEC (6 mg/kg.- d) and reevaluated 6
to 12 d after starting therapy for: (A) the percentage of cells recovered
by bronchoalveolar lavage that were eosinophils; (B) the concentration
of lung eosinophils in the epithelial lining fluid of the lower respiratory
tract; and (C) the change in pulmonary function tests, vital capacity
and FEVY, over the same time period. Three individuals were reevalu-
ated I yr later and the same parameters were evaluated.
and blood continued to fall and the lung function continued to
improve.
Lower respiratory tract inflammation in acute,
untreated TPE
The observation that acute, untreated TPE is characterized by
an intense eosinophilic inflammatory process in the lower re-
spiratory tract is compatible with other clinical and morpholog-
ical observations in this disease. First, although the sputum is
scanty in acute TPE, the classic studies of the disease by Wein-
garten (22) noted that some individuals produce a sputum with
clumps of eosinophils and Charcot-Leyden crystals. Second, al-
though little data is available, the morphologic description of
the lung parenchyma in acute TPE suggests that the inflam-
mation consists mainly of eosinophils with a variable proportion
of mononuclear phagocytes and lymphocytes (6, 9, 10, 12, 13).
Thus, it appears that the inflammatory cells recovered by lavage
in acute TPE are likely representative of the overall lower re-
spiratory tract inflammation taking place in these individuals.
In contrast to the findings in acute TPE, pulmonary eosin-
ophils are rarely present in the normal lung, whether evaluated
by bronchoalveolar lavage (19) or biopsy (23). Both light and
electron microscopic studies of normal lung parenchyma (23)
and studies in which normal lung parenchyma has been teased
apart to sample both the interstitial and alveolar epithelial cell
populations (24, 25) have shown that eosinophils are rarely found
on the normal epithelial surface. At least two possibilities, not
necessarily mutually exclusive, could explain the accumulation
of eosinophils in the lung in acute TPE.
First, since these individuals have an intense blood eosino-
philia, it is possible that eosinophils distribute to the lung pa-
renchyma passively through "leaky" endothelial and epithelial
cell layers. While such processes may be involved, there are many
other disorders associated with blood eosinophilia in which eo-
sinophils do not accumulate in the lung parenchyma (26). Fur-
thermore, direct quantitation ofthe eosinophil concentration in
the epithelial lining fluid recovered from the lower respiratory
tract of individuals with acute TPE shows it to be at least sev-
eralfold greater than that of the eosinophil concentration in
blood, i.e., there is a gradient ofeosinophils from blood to lung
that could not be explained by passive mechanisms and spillover
from the blood.
Second, the accumulation of eosinophils in the lower respi-
ratory tract of these individuals could potentially be modulated
by eosinophil-specific chemotactic signals originating within the
alveolar structures. While very little is known about such che-
motactic signals specifically in the human lower respiratory tract,
eosinophil-specific chemotactic factors have been described as
the products of mast cells (27, 28), lymphocytes (29-31), and
mononuclear phagocytes (32-34). Furthermore, complement
components, too, can generate eosinophil chemotactic fac-
tors (35).
Regardless of the mechanism responsible for eosinophil ac-
cumulation in the acute TPE lung, it is reasonable to hypothesize
that microfiliariae within the lung could be the initiating signal.
In this context, serial sectioning of the few available lung biopsies
from individuals with acute TPE has demonstrated degenerating
microfiliariae within the lung parenchyma, often in association
with eosinophils, alveolar macrophages, epithelioid cells, and
foreign body giant cells (9, 10, 12, 13). These microfiliariae or
their products could initiate the release of chemotactic signals
secondarily from inflammatory cells or inflammatory reactants
or they themselves may be chemotactic for eosinophils, as has
been described for some other nematode parasites (36).
While inflammatory processes in which eosinophils dominate
are very unusual in the lower respiratory tract, eosinophils have
been described as contributing to the alveolitis of chronic eosin-
ophilic pneumonia, idiopathic pulmonary fibrosis, histiocytosis
X, hypersensitivity pneumonitis and sarcoidosis (37). In most
of these cases, however, the eosinophil inflammation is mild,
usually representing < 5% of the total inflammatory cell pop-
ulations recovered from the lower respiratory tract (38). In ad-
dition to these interstitial lung diseases, the individuals with
asthma evaluated in the present study had a small percentage
of eosinophils recovered by lavage, consistent with that observed
in other studies (39).
Potential role oflung eosinophils in the derangement ofthe
lower respiratory tract in TPE
Although the mechanism by which eosinophils may be attracted
to the lung in acute TPE is unknown, it is logical to consider
that these cells play an important role in the pathogenesis of
disease, since eosinophils have already been shown to be capable
of injuring normal lung parenchymal cells, alveolar epithelial
cells, fibroblasts, pleural mesothelial cells, and bronchial epithe-
lial cells (38, 40-42). The mechanisms by which eosinophils do
this are unclear, although oxidant radicals have been implicated
(40) as has major basic protein, the primary component of the
eosinophil granule core (41, 42). Eosinophils also carry a per-
oxidase capable of converting H202 to the hypohalide anion
(42), which is toxic to normal cells. Furthermore, human eosin-
ophils contain a collagenase capable of cleaving collagen types
I and III, the two major collagens of the alveolar interstitium
(38). In the context of TPE, it is also conceivable that the eosin-
ophils may play a role in the bronchospasm observed in acute
TPE, perhaps by virtue of the ability of these cells to release
leukotrienes (4 1).
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Evaluation of the morphology of the eosinophils recovered
from the lungs of individuals with acute TPE suggested these
eosinophils were in an activated state. In this regard, the lung
eosinophils showed marked degranulation, a process that follows
eosinophil activation (44-57). This observation is consistent with
the correlation of eosinophil activation with eosinophil degran-
ulation observed in a variety of circumstances. For example,
eosinophils lavaged from asthmatic individuals show loss of
central cores and release of granules into the cytoplasm both
after allergen challenges and during environmental exposure (51).
In chronic eosinophilic pneumonia, eosinophils in the alveolar
spaces and the interstitium have loss of granules and granule
components (52-54) and macrophages from these individuals
appear to have ingested alveolar eosinophil granules and Charcot-
Leyden crystals (55). Furthermore, major basic protein, an im-
portant component of eosinophil granules, is detected in high
quantities in pleural fluid and in biopsy material in the lower
respiratory tract in chronic eosinophilic pneumonia (54). In hy-
pereosinophilic syndrome, degranulated and vacuolized blood
eosinophils correlate with tissue damage including endomyo-
cardial injury (56). In facial edema with hypereosinophilia (57)
degranulated eosinophils have been found in the dermis with
extracellular major basic protein localized by immunofluorescent
staining. These observations, together with the knowledge that
eosinophil granule components can injure normal tissues (47-
50), support the concept that lung eosinophils in acute TPE
release mediators that are responsible, at least in part, for many
of the symptoms and pathophysiologic abnormalities observed
in this disorder.
Consistent with the hypothesis that the intense eosinophilic
alveolitis of acute TPE is responsible, at least in part, for the
derangements to the lowet respiratory tract in this disease is the
observation that when individuals with acute TPE are treated
with DEC the improvement in lung function is concurrent with
the resolution of the intense eosinophilic inflammation in the
lower respiratory tract. However, it is interesting to speculate
that, although the eosinophil is capable of injuring the normal
lung parenchyma, there may be a threshold in the eosinophil
burden to the lower respiratory tract below which the lung pa-
renchyma can handle the "injurious" inflammatory potential
of the eosinophil. In this context, the intense eosinophilic infil-
tration of acute TPE appears to be far less damaging to the al-
veolar structures than the more mild neutrophilic inflammation
of a disorder such as idiopathic pulmonary fibrosis in which the
derangements to the lower respiratory tract are severe (37).
DEC therapy ofacute TPE
DEC is a piperazine derivative widely used in the treatment of
filarial infections (58). Most individuals with acute TPE respond
to the DEC therapy within I to 3 wk with a progressive reduction
in symptoms, clearing of the chest x-ray, reduction in the blood
eosinophil count, and improvement in lung function (5, 7, 8,
58, 59). After therapy with DEC, there is a reduction in serum
IgE and filarial specific IgG which occurs more gradually
(58, 59).
The mechanisms of action ofDEC are unclear. In vitro it is
inactive against microfilariae (60), although it is generally ap-
preciated to be "opsonic" for microfilariae in vivo causing their
rapid clearance from the blood of microfilaremic individuals
(58) and to be filaricidal against both microfilariae and the adult
worms in vivo (58, 60). Other in vitro studies also suggesting
that DEC acts to augment inflammatory processes directed
against the microfilariae include the demonstration that DEC
enhances the adherence of eosinophils to microfilariae (61, 63),
activates complement associated with microfilariae (64), gen-
erally stimulates granulocyte adherence (62, 63), and likely
stimulates eosinophils to release preformed granule proteins such
as major basic protein onto the surface of microfilariae (65).
Despite the fact that how DEC acts in acute TPE is not fully
understood, the present study suggests at least one consequence
ofDEC therapy in this disease is the suppression of the intense
eosinophilic alveolitis. Since eosinophils can clearly injure the
normal lung parenchyma, this observation is consistent with the
concept that the improvement in symptoms, x-ray and lung
function observed in individuals with acute TPE treated with
DEC results, at least in part, from the direct and/or indirect
suppression ofthe exaggerated eosinophilic inflammation ofthe
lower respiratory tract that characterizes this disorder.
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